{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:03:08Z","timestamp":1787068988641,"version":"build-2736575974"},"reference-count":60,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the efficacy and safety of maribavir for management of cytomegalovirus (CMV) in solid organ transplant recipients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>\n                      A literature search of PubMed and the Cochrane Controlled Trials Register (1960 to early July 2022) was performed using the following search terms:\n                      <jats:italic toggle=\"yes\">maribavir, 1263W94<\/jats:italic>\n                      , and\n                      <jats:italic toggle=\"yes\">cytomegalovirus<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>All relevant English-language studies were reviewed and considered, with a focus on phase 3 trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>\n                      Maribavir, an orally available benzimidazole riboside with minimal adverse effects, was originally studied for universal prophylaxis in phase 3 trials but failed to demonstrate noninferiority over placebo and oral ganciclovir. It was effective for preemptive treatment in a dose-finding Phase 2 study. Maribavir is FDA approved for treatment of refractory\/resistant CMV infection based on improved response rate at 8 weeks compared with investigator-assigned therapy (IAT) when initiated at median viral loads less than approximately 10 000 IU\/mL (55.7% vs 23.9%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). Recurrence after 8-week treatment for refractory\/resistant CMV was high (maribavir 50% vs IAT 39%). Significant drug interactions exist and must be managed by a pharmacotherapy expert to prevent harm.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice:<\/jats:title>\n                    <jats:p>The addition of maribavir to the antiviral armamentarium should improve the management of refractory\/resistant CMV, allowing early transition from toxic, high-cost, intravenous agents such as foscarnet and outpatient management. Optimal timing of initiation, duration, and potential alternative uses are unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Future studies are needed to fully elucidate the role of maribavir in the management of CMV after transplant.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280221118959","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T01:44:25Z","timestamp":1661391865000},"page":"597-608","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Maribavir for the Management of Cytomegalovirus in Adult Transplant Recipients: A Review of the Literature and Practical Considerations"],"prefix":"10.1177","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3149-6558","authenticated-orcid":false,"given":"Hanna L.","family":"Kleiboeker","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of Wisconsin Hospital and Clinics, Madison, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian L.","family":"Descourouez","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Wisconsin Hospital and Clinics, Madison, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas T.","family":"Schulz","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Wisconsin Hospital and Clinics, Madison, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier A.","family":"Mandelbrot","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon S.","family":"Odorico","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Transplantation, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Rice","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hepatology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Saddler","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannina A.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6088-9727","authenticated-orcid":false,"given":"Margaret R.","family":"Jorgenson","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Wisconsin Hospital and Clinics, Madison, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,8,24]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2006.00639.x."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002191."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13512."},{"key":"e_1_3_2_5_2","unstructured":"Valganciclovir. Lexicomp. Published May 18 2022. Accessed May 31 2022. https:\/\/online.lexi.com\/lco\/action\/doc\/retrieve\/docid\/uofwisconsin_f\/3680860?cesid=1To5IqCNfvr&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DvalGANciclovir%26t%3Dname%26acs%3Dtrue%26acq%3Dvalgan#"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00009-10."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001418."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1987."},{"key":"e_1_3_2_9_2","unstructured":"LIVTENCITY. Highlights of Prescribing Information. Published November 2021. Accessed May 6 2022. https:\/\/content.takeda.com\/?contenttype=pi&product=liv&language=eng&country=usa&documentnumber=1"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2365-2372.2002."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.7.2186-2192.2003."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01575-09."},{"key":"e_1_3_2_13_2","unstructured":"Foscarnet. Lexicomp. Published May 3 2022. Accessed May 31 2022. https:\/\/online.lexi.com\/lco\/action\/doc\/retrieve\/docid\/uofwisconsin_f\/3679982?cesid=3C6UyXULJIy&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dfoscarnet%26t%3Dname%26acs%3Dfalse%26acq%3Dfoscarnet#"},{"key":"e_1_3_2_14_2","unstructured":"Cidofovir. Lexicomp. Published April 28 2022. Accessed May 31 2022. https:\/\/online.lexi.com\/lco\/action\/doc\/retrieve\/docid\/uofwisconsin_f\/3680088?cesid=8E6hVDV0yV6&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dcidofovir%26t%3Dname%26acs%3Dtrue%26acq%3Dcido#"},{"key":"e_1_3_2_15_2","unstructured":"Letermovir. Lexicomop. Published July 8 2022. Accessed July 14 2022. http:\/\/online.lexi.com\/lco\/action\/doc\/retrieve\/docid\/uofwisconsin_f\/6566007?cesid=3ebVYXxg6LE&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dletermovir%26t%3Dname%26acs%3Dtrue%26acq%3Dletermo#"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.9.2969-2976.2002."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.4.1334-1342.2003."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S303052."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.4.1130-1135.2006."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.600."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006296765."},{"key":"e_1_3_2_22_2","unstructured":"Song IH Ilic K Wu J. Pharmacokinetics of maribavir in subjects with moderate hepatic impairment. ATC Meeting Abstracts. Published May 30 2020. Accessed May 6 2022. https:\/\/atcmeetingabstracts.com\/abstract\/pharmacokinetics-of-maribavir-in-subjects-with-moderate-hepatic-impairment\/"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00951-07."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02768.x."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-121558"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70024-X."},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2012.04231.x."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714656."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2010.00550.x."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2016.12.006."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy706."},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab988."},{"key":"e_1_3_2_33_2","unstructured":"Highlights of prescribing information for Prevymis. Published November 2017. Accessed June 6 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209939Orig1s000 209940Orig1s000lbl.pdf"},{"key":"e_1_3_2_34_2","unstructured":"Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002). ClinicalTrials.gov Identifier: NCT03443869. Accessed June 7 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03443869"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1086\/339329"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.4849"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01413.x"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.04.016."},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.3138."},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13864."},{"key":"e_1_3_2_41_2","unstructured":"Avery RK Blumberg EA Florescu D et al Randomized phase 3 open-label study of Maribavir vs investigator-assigned therapy for refractory\/resistant cytomegalovirus infection in transplant recipients: subgroup analyses of efficacy by organ. ATC Abstracts. Published June 7 2021. Accessed June 1 2022. https:\/\/atcmeetingabstracts.com\/abstract\/randomized-phase-3-open-label-study-of-maribavir-vs-investigator-assigned-therapy-for-refractory-resistant-cytomegalovirus-infection-in-transplant-recipients-subgroup-analyses-of-efficacy-by-organ\/"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1086\/653122."},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-330."},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2019.104616."},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa462."},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab029."},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00577-06."},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2018.07.013."},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13585."},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13693."},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12814."},{"key":"e_1_3_2_52_2","unstructured":"Takeda Patient Support. Patient Support For Livtencity. Accessed May 6 2022. https:\/\/www.takedapatientsupport.com\/#need-assistence"},{"key":"e_1_3_2_53_2","unstructured":"Drug Search. ForwardHealth. Accessed July 22 2022. https:\/\/www.forwardhealth.wi.gov\/WIPortal\/Subsystem\/Provider\/DrugSearch.aspx"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx163.1967"},{"key":"e_1_3_2_55_2","unstructured":"Centers for Disease Control and Prevention. Body Measurements. Published September 10 2021. Accessed July 24 2022. https:\/\/www.cdc.gov\/nchs\/fastats\/body-measurements.htm"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13617."},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15183."},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix696."},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1879."},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13766."},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13189."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221118959","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280221118959","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221118959","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:17:03Z","timestamp":1777375023000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280221118959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1177\/10600280221118959"],"URL":"https:\/\/doi.org\/10.1177\/10600280221118959","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,24]]}}}